Acute Changes in Serotonin Detected by AI-designed Serotonin Sensor Reporter: Adina Hazan, PhD With 14 receptors and expression in central and peripheral nervous system, serotonin is an essential modulatory molecule. It plays critical roles in a multitude of functions, including addiction, appetite, blood pressure, digestion, and sleep. The clinical implications of this is clearly […]
Search Results for 'Serotonin'
Acute Changes in Serotonin Detected by AI-designed Serotonin Sensor
Posted in AI, Artificial Intelligence - Breakthroughs in Theories and Technologies, Artificial Intelligence - General, Behavior, Cell Biology, Cell Biology, Signaling & Cell Circuits, Circadian Rhythm and Sleep, Innovations in Neurophysiology & Neuropsychology, Neurological Diseases, Neuroscience, tagged acetyl choline sensor (iAChSnFR), Central Nervous System, Mutagenesis, periplasmic binding proteins (PBPs), reuptake inhibition of serotonin on December 30, 2020| Leave a Comment »
Not Lower Levels of Serotonin, but Damaged Brain Synapses as the Origin for Mental Depression
Posted in Bio Instrumentation in Experimental Life Sciences Research, Biological Networks, Gene Regulation and Evolution, Cerebrovascular and Neurodegenerative Diseases, Disease Biology, Small Molecules in Development of Therapeutic Drugs, Innovations in Neurophysiology & Neuropsychology, Molecular Genetics & Pharmaceutical, Personalized and Precision Medicine & Genomic Research, Pharmaceutical R&D Investment, Pharmacogenomics, Population Health Management, Genetics & Pharmaceutical, tagged Antidepressant, genetics, Gurwitz, Pexeva coupon, Selective serotonin reuptake inhibitor, SSRI on December 9, 2013| 1 Comment »
Not Lower Levels of Serotonin, but Damaged Brain Synapses as the Origin for Mental Depression Reporter: Aviva Lev-Ari, PhD, RN Israeli discovery matches right antidepressant for each patient Genetic study suggest that depression may be caused not by lack of serotonin, but because of damage to the brain synapses. It all comes down to a […]
Neuroscience impact of synaptic pruning discovery
Posted in Alzheimer's Disease, Autism Spectrum Disorders, Cell Biology, Cell Biology, Signaling & Cell Circuits, Cerebrovascular and Neurodegenerative Diseases, Disease Biology, Etiology, Neurodegenerative Diseases, Neurological Diseases, Neuroscience, tagged adolescent onset, dendritic pruning, neurodegenerative diseases, Neuroscience, Schizophrenia on May 3, 2016| Leave a Comment »
Neuroscience impact of synaptic pruning discovery Larry H. Bernstein, MD, FCAP, Curator LPBI Synaptic Pruning Discovery May Lead to New Therapies for Neuro Disorders GEN 3 May, 2016 http://www.genengnews.com/gen-news-highlights/synaptic-pruning-discovery-may-lead-to-new-therapies-for-neuro-disorders/81252680/ Source: NIH http://www.genengnews.com/Media/images/GENHighlight/thumb_May3_2016_NIH_CRANPuzzleBrain_AdolescentBrain2247219834.jpg A research team led by scientists at SUNY Downstate Medical Center has identified a brain receptor that appears […]
Reversal of Alzheimer Disease in Fruit Flies
Posted in Alzheimer's Disease, Cognition, Neurodegenerative Diseases, Neuroscience, Pharmacotherapy and Cell Activity, tagged Alzheimer Disease, fruit flies, KYNA synthesis, TDO-deficient flies on May 2, 2016| Leave a Comment »
Reversal of Alzheimer Disease in Fruit Flies Curator: Larry H. Bernstein, MD, FCAP Reversal of AD in fruit flies Transatlantic team reverses Alzheimer’s, Parkinson’s symptoms in fruit flies by Amirah Al Idrus | Apr 26, 2016 http://www.fiercebiotech.com/research/transatlantic-team-reverses-alzheimer-s-parkinson-s-symptoms-fruit-flies Scientists from the University of Leicester and the University of Maryland have reversed Alzheimer’s and Parkinson’s symptoms by inhibiting […]
Schizophrenia genomics
Posted in Genome Biology, Mutant Gene Expression, Neurological Diseases, Neuroscience, Schizophrenia, tagged Akt/PKB, autism spectrum disorders (ASDs), Chromatin, copy number variation (CNV), Epigenetics, histone methylation, Lymphocyte, methyl-CpG-binding domain (MBD), PDK2, PI3K/PTEN, Postmortem Brain, Rett syndrome, Schizophrenia, single nucleotide polymorphism (SNP) on March 15, 2016| Leave a Comment »
Schizophrenia genomics Larry H. Bernstein, MD, FCAP, Curator LPBI Histone Methylation at H3K9; Evidence for a Restrictive Epigenome in Schizophrenia Kayla A. Chase,1David P. Gavin,1Alessandro Guidotti,1 and Rajiv P. Sharma1 Schizophr Res. 2013 Sep; 149(0): 15–20. doi: 10.1016/j.schres.2013.06.021 Epigenetic changes are stable and long-lasting chromatin modifications that regulate genomewide and local gene activity. […]
AGENDA for Oligonucleotide Therapeutics and Delivery, April 4-5, 2016, HYATT Hotel, Cambridge, MA
Posted in BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Biological Networks, Gene Regulation and Evolution, Gene Regulation, Gene Regulation and Evolution, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Genomic Testing: Methodology for Diagnosis, Genomics Pharmacy on December 3, 2015| Leave a Comment »
AGENDA for Oligonucleotide Therapeutics and Delivery, April 4-5, 2016, HYATT Hotel, Cambridge, MA Reporter: Aviva Lev-Ari, PhD, RN Oligonucleotide Therapeutics and Delivery http://www.healthtech.com/oligonucleotide/ Register by January 8 and save up to $350 Oligonucleotide–based therapeutics have long formed the third major drug development platform, specifically focused on modulating gene expression by targeting […]
Teva Wins Breakthrough Therapy Designation for Tardive Dyskinesia Candidate
Posted in Cerebrovascular and Neurodegenerative Diseases, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Uncategorized, tagged Monoamines, movement disorders, parkinson's, tardive dyskenesia on November 20, 2015| Leave a Comment »
FDAnews Drug Daily Bulletin Pharmaceuticals / Submissions and Approvals Teva Wins Breakthrough Therapy Designation for Tardive Dyskinesia Candidate Nov. 16, 2015 Teva Pharmaceutical Industries has won the FDA’s breakthrough therapy designation for SD-809 for the treatment of moderate to severe tardive dyskinesia. An oral, small molecule inhibitor of vesicular monoamine 2 transporter, SD-809 (deutetrabenazine) is […]